Received: 7 May 2021
Accepted: 20 October 2021
First Online: 19 November 2021
: Written informed consent was obtained from all patients prior to the start of the study. The study protocol and all amendments were approved by the independent ethics committee or institutional review board for each center. This study was carried out in accordance with the ethical principles of the Declaration of Helsinki.
: Not applicable.
: <b>RG</b> serves as consultant to Almirall; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi Genzyme; Sun Pharmaceutical Industries, Inc.; and 4SC; has received travel grants and honoraria for lectures from Almirall; Amgen; Bayer; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; and Sun Pharmaceutical Industries, Inc.; and has received research funding from Amgen; Johnson & Johnson; Merck Serono; Novartis; and Sun Pharmaceutical Industries, Inc. <b>CR</b> has received consulting fees from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, and Sanofi. <b>CL</b> has acted as a speaker for, served on an advisory board for, and received honoraria from Bristol-Myers Squibb, Roche, Novartis, and Merck Sharp & Dohme. <b>DS</b> has acted as a speaker for, served on an advisory board for, received research funding from, and/or received honoraria from 4SC Discovery, Agenus, Amgen, Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Grünenthal Group, Immunocore, Incyte, LEO Pharma, Merck Serono, Merck Sharp & Dohme, Mologen, Novartis, Pfizer, Philogen, Pierre Fabre, Regeneron Pharmaceuticals, Roche, Sanofi, and Sysmex. <b>NS</b>, <b>RA</b>, and <b>SM</b> are employees of Sun Pharmaceutical Industries, Inc. <b>RD</b> has served on advisory boards and as a consultant for Amgen; Bristol-Myers Squibb; Catalym; Merck Sharpe and Dohme; Novartis Pharmaceutical Corporation; Pierre Fabre; Roche; Sanofi; Second Genome; Sun Pharmaceutical Industries, Inc.; and Takeda.